Dinoprostone
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
DINOPROSTONE: Drug Repurposing Evaluation — No Predicted Indications Available
One-Sentence Summary
Dinoprostone (Prostaglandin E2) is a registered drug in Malaysia with 3 active marketing authorizations. However, the TxGNN model did not generate any predicted new indications for this compound, and critical data gaps in mechanism of action, safety information, and license details prevent a meaningful repurposing evaluation at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (license details incomplete) |
| Predicted New Indication | None — no predictions generated by TxGNN |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN prediction was generated for Dinoprostone. The predicted_indications array is empty, meaning the model did not identify any drug–disease pair that met the scoring threshold for this compound.
Currently, detailed mechanism of action data is not available in the evidence pack. Based on publicly known information, Dinoprostone is a synthetic form of Prostaglandin E2 (PGE2), which acts on EP receptors to promote cervical ripening, stimulate uterine smooth muscle contraction, and modulate inflammatory responses. It is primarily used in obstetrics for labour induction and cervical preparation.
The absence of TxGNN predictions may be attributable to one or more of the following factors:
- Limited KG connectivity — Dinoprostone’s DrugBank node may have few edges in the TxGNN knowledge graph, reducing the model’s ability to infer novel disease associations.
- Narrow therapeutic profile — As a locally-acting prostaglandin analogue with a very specific obstetric use case, the compound may lack the pharmacological breadth that typically generates repurposing candidates.
- Data gaps upstream — The absence of mapped original indications and MOA data may have impaired the prediction pipeline’s ability to process this drug.
Clinical Trial Evidence
Currently no related clinical trials registered — no predicted indication was generated to search against.
Literature Evidence
Currently no related literature available — no predicted indication was generated to search against.
Malaysia Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| (not provided) | (not provided) | (not provided) | (not provided) |
| (not provided) | (not provided) | (not provided) | (not provided) |
| (not provided) | (not provided) | (not provided) | (not provided) |
Note: 3 marketing authorizations are recorded in the NPRA registry, but the license details (authorization numbers, product names, dosage forms, and approved indication text) were not populated in the evidence pack. This data gap must be remedied before any further evaluation.
Safety Considerations
Please refer to the package insert for safety information.
All safety fields (key warnings, contraindications, drug-drug interactions) are currently unavailable. No DDI records were found in the DrugBank query.
Conclusion and Next Steps
Decision: Hold
Rationale: No repurposing candidates were predicted by TxGNN for Dinoprostone. Combined with multiple blocking data gaps (empty license details, missing MOA, missing safety data), there is insufficient information to proceed with any repurposing evaluation.
To proceed, the following is needed:
- Resolve Data Gap DG001 (Blocking): Obtain NPRA product insert / package insert PDFs and parse warnings and contraindications
- Resolve Data Gap DG002 (High): Query DrugBank API for Dinoprostone’s mechanism of action and pharmacodynamics
- Complete license details: Re-query the NPRA database to populate authorization numbers, product names, dosage forms, and approved indication text for all 3 registrations
- Investigate TxGNN pipeline: Confirm that Dinoprostone (DB00917) is correctly mapped in the knowledge graph and that the prediction pipeline processed it without errors
- If predictions become available after data remediation: Re-run the evaluation with a complete evidence pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.